Floatz logo

Danvatirsen

Ascites

National Cancer Institute (NCI)Phase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Ascites cohort.

Asset / SponsorPhaseRating
NORMAL HUMAN SERUM ALBUMIN
Centro Medico Issemym
Phase 4BBB
Tolvaptan
Konkuk University Medical Center
Phase 4BBB
FUROSEMIDE
University of Palermo
Phase 4BB
Rifaximin
Centre Hospitalier Universitaire de Besancon
Phase 4BB
CARVEDILOL
Asian Institute Of Medical Sciences
Phase 4BB

View all 36 →

Same molecule, other indications

Danvatirsen is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
Early-stageDormant
B
Indicative ·
57 / 100
View asset →
colorectal carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →